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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1263The NHLBI Working Group: Heart Transplantation Research in the Next DecadeMonica R. Shah, Randall C. Starling, Lisa Schwartz Longacre, Mandeep R. Mehra, on behalf of the
Working Group Participants
The National Heart, Lung, and Blood Institute (NHLBI) recently sponsored a workshop
entitled “Cardiac Transplantation Research in the Next Decade: A Goal to Evidence Based
Outcomes.” The participants identified the most urgent knowledge gaps regarding heart
transplantation and divided them into 4 specific research directions: 1) enhanced phenotypic
characterization of the pre-transplant population; 2) donor–recipient optimization strategies;
3) individualized immunosuppression therapy; and 4) investigations of immune and
nonimmune factors affecting late cardiac allograft outcomes. The participants strongly urged
concerted efforts to enroll every transplant recipient into a clinical study and to increase
collaborative networks given the small number of transplants that occur every year.EDITORIALS AND VIEWPOINTS SPECIAL ARTICLE1270Lessons Learned From a Federal Audit of ICD ImplantsJonathan S. Steinberg, Suneet Mittal
The federal government has investigated several institutions for implantable cardioverter-
defibrillator (ICD) procedures that may have been in violation of the criteria set forth in a
National Coverage Determination. Steinberg and Mittal describe their experience and
responses to such an audit. They identified 7 categories of patients flagged as inappropriate:
1) those that truly were inappropriate; 2) secondary prevention patients where the index event
was not properly recognized because it occurred at outside facility; 3) patients with
cardiomyopathy presenting with syncope; 4) trivial cardiac enzyme elevation coded as acute
MI; 5) ICD implantation when the acute device need was bradycardia; 6) PCI not
anticipated to improve chronic LV dysfunction within 90 days; and 7) ICD implantation near
the end of the 90 day post-revascularization period. A careful audit found that only 15% of
the cases flagged as inappropriate failed to have an acceptable explanation rendering them
appropriate. The authors conclude with a description of the procedures they have implemented
to reduce the risk of future audits while still ensuring optimal patient care.(continued on page A-18)
APRIL 3, 2012 (continued) A-18CLINICAL RESEARCH IMAGING IN TRANSCATHETER AORTIC VALVE REPLACEMENT1275CT Imaging Improves Accuracy of Aortic Annular Sizing for TAVRHasan Jilaihawi, Mohammad Kashif, Gregory Fontana, Azusa Furugen, Takahiro Shiota, Gerald Friede,
Rakhee Makhija, Niraj Doctor, Martin B. Leon, Raj R. Makkar
Recent studies have shown clear discrepancies between echocardiographic and computed
tomographic (CT) aortic annular measurements for sizing in patients undergoing transcatheter
aortic valve replacement (TAVR). Jilaihawi and colleagues sought to determine if these differences
were clinically relevant. Cross-sectional CT measurements were slightly more predictive for post-
TAVR paravalvular regurgitation then circumference-derived measurements, while traditional
echocardiographic measures were not predictive. These data support using cross-sectional CT
measures as the gold standard for aortic annular sizing prior to TAVR.IMAGING IN TRANSCATHETER AORTIC VALVE REPLACEMENT
1287Imaging in TAVR Aortic Annular Assessment by MDCT Predicts Moderate
or Severe Paravalvular Regurgitation After TAVRAlexander B. Willson, John G. Webb, Troy M. LaBounty, Stephan Achenbach, Robert Moss, Miriam Wheeler,
Christopher Thompson, James K. Min, Ronen Gurvitch, Bjarne L. Norgaard, Cameron J. Hague,
Stefan Toggweiler, Ronald Binder, Melanie Freeman, Rohan Poulter, Steen Poulsen, David A. Wood,
Jonathon Leipsic
Willson and colleagues performed a multicenter, retrospective analysis of over 100 patients
who underwent multidetector computed tomography (MDCT) prior to transcatheter aortic
valve replacement (TAVR) to determine if MDCT-derived aortic annular dimensions could
predict which patients would develop para-aortic regurgitation (PAR) after the procedure.
Moderate or severe PAR was associated with tissue heart valve (THV) undersizing compared
to MDCT measurements, while annular eccentricity was not. MDCT-derived annular
measurements, particularly the mean diameter and the cross-sectional area, are predictive of
moderate or severe PAR following TAVR.(continued on page A-19)
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1295Patients With Metabolic Syndrome at Increased Risk for
Arrhythmia Recurrence After AF AblationSanghamitra Mohanty, Prasant Mohanty, Luigi Di Biase, Bai Rong, Agnes Pump, Pasquale Santangeli,
David Burkhardt, Joseph G. Gallinghouse, Rodney Horton, Javier E. Sanchez, Shane Bailey, Jason Zagrodzky,
Andrea Natale
Metabolic syndrome (MS), a pro-inflammatory state with hypertension, diabetes, dyslipidemia,
and obesity, appears to pre-dispose patients to atrial fibrillation (AF). Mohanty and colleagues
investigated whether or not MS affects the outcomes of catheter ablation of AF. In 1,500
consecutive AF ablation patients, subjects with MS were more likely to have arrhythmia
recurrence during 2 years of follow-up. This was driven mostly by higher recurrence rates in
those with permanent AF. These results help to clarify the relationship between MS and AF
and will help to counsel patients on the likelihood of success of AF ablation procedures.Editorial Comment: Samuel J. Asirvatham, Zhen Jiao, p. 1302CARDIAC PHARMACOLOGY
1304Differences in the Pharmacokinetic and Pharmacodynamic Effects
of PPIs on ClopidogrelAndrew L. Frelinger III, Ronald D. Lee, Darcy J. Mulford, Jingtao Wu, Sai Nudurupati, Anu Nigam,
Julie K. Brooks, Deepak L. Bhatt, Alan D. Michelson
The metabolism of clopidogrel into it active metabolite requires cytochrome P450s, including
CYP2C19. Felinger and colleagues studied whether various proton pump inhibitors (PPIs)
affect the pharmacokinetics and pharmacodynamics of clopidogrel by studying subjects who
were homozygous for CYP2C19 extensive metabolizer genotype. The area under the curve
for clopidogrel active metabolite (clopidogrelAM) decreased significantly with omeprazole and
esomeprazole but not with dexlansoprazole or lansoprazole. Results were similar for the effect
on VASP platelet reactivity index. These results suggest that the potential of PPIs to
attenuate clopidogrel efficacy could be minimized by using dexlansoprazole or lansoprazole
rather than esomeprazole or omeprazole in patients who require both.(continued on page A-20)
APRIL 3, 2012 (continued) A-20VALVULAR HEART DISEASE1312Similar Efficacy With MitraClip Therapy in Patients With and Without AFHoward C. Herrmann, Zachary M. Gertz, Frank E. Silvestry, Susan E. Wiegers, Y. Joseph Woo,
James Hermiller, Douglas Segar, David Heimansohn, William Gray, Shunichi Homma, Michael Argenziano,
Andrew Wang, James Jollis, Mark B. Lampert, John Alexander, Laura Mauri, Elyse Foster, Donald Glower,
Ted Feldman
The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) compared the
MitraClip (Abbott Vascular, Abbott Park, Illinois) procedure to surgical repair for patients
with mitral regurgitation (MR). Hermann and colleagues performed a substudy to explore the
impact of atrial fibrillation (AF) in their patients, whether treated with the MitraClip or
surgically. Pre-existing AF was found in patients who were older, had more advanced disease,
and were more likely to have functional MR. There were similar technical and clinical
outcomes to 12 months in patients with and without AF treated with the MitraClip. There
was no interaction between rhythm and MR reduction with either treatment modality at
12 months. AF is associated with more advanced valvular disease and noncardiac
comorbidities, but does not seem to affect the therapeutic benefits of MitraClip therapy.PRE-CLINICAL RESEARCH1320Improved Results With Temporally Separated VEGF and Ang-1 Gene TransferAlexandra H. Smith, Michael A. Kuliszewski, Christine Liao, Dmitriy Rudenko, Duncan J. Stewart,
Howard Leong-Poi
Single gene delivery of vascular endothelial growth factor (VEGF) results in immature
neovessels that ultimately regress. Smith and colleagues notes that angiopoietin (Ang)-1 acts
later to induce vessel maturation and, therefore, studied giving Ang-1 4 weeks after VEGF
transfection. Unilateral hindlimb ischemia was induced in rats who then underwent
ultrasound-mediated gene delivery of plasmid deoxyribonucleic acid. Compared to VEGF
alone and VEGF/Ang-1 simultaneously, temporally separated VEGF and Ang-1 delivery,
resulted in improved blood flow, vessel density and flow reserve at 8 weeks. These results
confirm that delivering Ang-1 after VEGF has induced neovascularization leads to more
sustained and functional improvements.
